

RESEARCH ARTICLE

OPEN ACCESS

# Phenotypic and molecular characterisation of efflux pump genes in clinical isolates of *Serratia marcescens*

Characterisation of Efflux Pumps in *S. marcescens*

Khadim MM<sup>1</sup>, Hussein AN<sup>1</sup><sup>ID</sup>

<sup>1</sup>College of Education, Al-Qadisiyah University, Iraq

Submitted: 29<sup>th</sup> April 2025

Accepted: 2<sup>nd</sup> July 2025

Published: 31<sup>st</sup> December 2025

<sup>ID</sup>: Orcid ID

## Abstract

**Objective:** This study focuses on identifying and understanding efflux pump genes in *Serratia marcescens* bacteria collected from clinical samples. We aimed to ascertain how these bacteria resist antibiotics by characterising their outward features and genetic makeup.

**Methods:** We examined twenty isolates of *S. marcescens*, from urinary tract infections, diarrheal cases, and blood infections. To identify these bacteria, we used standard laboratory tests. We then tested whether they had active efflux pumps with a simple dye-based method called the ethidium bromide-agar cartwheel test. After that, we extracted their DNA and used PCR to look for five specific genes linked to efflux activity: SdeXY-Y, SsmE, SdeCDE-D, SdeAB-B, and LUXR. We applied the usual PCR conditions with primers designed for each gene.

**Results:** Our results showed that nearly half of the isolates (8 out of 20) had active efflux pumps. The LUXR gene was found in all the bacteria, making it the most common. The SdeCDE-D gene was present in 95% of samples, SdeAB-B in 90%, SdeXY-Y in 60%, and SsmE in 45%. The presence of these genes varied depending on the type of sample, with the highest occurrence in blood and urinary tract infections. To review, we confirmed that multiple efflux pump genes are present in clinical *S. marcescens* isolates. Notably, LUXR, SdeCDE-D, and SdeAB-B are the most widespread.

**Conclusion:** These findings suggest that efflux pumps could play an important role in antibiotic resistance, emphasising the need for ongoing genetic monitoring for optimal management of multidrug-resistant infections.

**Keywords:** *Serratia marcescens*, Multidrug Resistance, Efflux Pumps, Polymerase Chain Reaction, Microbial Sensitivity Tests

## Plain English Summary

*Serratia marcescens* is a type of bacteria that can cause serious infections, especially in hospital patients. These bacteria are becoming increasingly resistant to treatment because they can resist many antibiotics. One way they do this is by using "efflux pumps", proteins that help the bacteria push antibiotics out of their cells before the drugs can work. In this study, we collected samples from patients in two hospitals in Iraq and identified 20 *S. marcescens* bacteria. We tested them in the lab to see if they used efflux pumps and checked their DNA to find specific genes linked to these pumps. We found that eight of the 20 bacteria showed signs of active efflux pumps. However, many more had the genes needed to make them. One gene, called LUXR, was found in all the bacteria and may help them communicate with each other and increase their resistance. Other genes, SdeCDE-D, SdeAB-B, SdeXY-Y, and SsmE, were also common and are known to help bacteria resist different antibiotics.

Correspondence:

Hussein, Azhar N

College of Education,

Al-Qadisiyah University,

Iraq

+9647811361151, [azhar.almousawi@qu.edu.iq](mailto:azhar.almousawi@qu.edu.iq)

Although we studied only a small number of samples, our results suggest that *S. marcescens* in this region may harbour hidden resistance traits. This makes infections harder to treat and underscores the need for improved testing and monitoring of antibiotic resistance. Understanding these resistance genes may also help scientists develop new treatments that block the efflux pumps, making antibiotics more effective.

## Introduction

*Serratia marcescens* is a Gram-negative, rod-shaped bacterium characterised by motility but lacking the ability to form spores. It belongs to the order Enterobacterales and is a member of the Enterobacteriaceae family (1). Recognised broadly as an opportunistic pathogen, it is known to cause a diverse array of infections acquired within healthcare settings. Although it was once regarded as a non-virulent organism, recent evidence has positioned *S. marcescens* as a clinically important pathogen involved in conditions such as pneumonia, urinary tract infections, bacteraemia, endocarditis, osteomyelitis, and infections associated with intravenous catheters (2, 3).

The ability of *S. marcescens* to persist in hospital environments is partly attributed to its remarkable adaptability and capacity to produce enzymes like DNases, enhancing its resilience in these settings (4). More critically, the bacterium exhibits resistance to multiple drugs, primarily driven by various mechanisms, including the active efflux of antibiotics through specialised transporter proteins.

Efflux pumps are transmembrane proteins responsible for removing toxic compounds, such as antibiotics, detergents, dyes, heavy metals, and antimicrobial molecules produced by the host, from bacterial cells (5, 6). These systems not only contribute to antibiotic resistance across multiple classes but also play integral roles in bacterial physiology, influencing processes like quorum sensing, biofilm development, and pathogenicity (7, 8). Their activity greatly enhances both innate and acquired antimicrobial resistance in clinical strains (9, 10).

Several efflux systems belonging to the resistance-nodulation-cell division (RND) family and the small multidrug resistance (SMR) family have been identified within *S. marcescens*. Prominent among these are the SdeXY, SdeCDE, and SdeAB systems, each associated with resistance to antibiotics such as fluoroquinolones, tetracyclines, and  $\beta$ -lactams (11, 12, 13, 14). Also, the SsmE gene encodes an SMR-type efflux pump linked to resistance against norfloxacin and ethidium bromide (Minato *et al.*, 2008). Though not a classical efflux gene, LUXR functions as a regulator of quorum sensing and may indirectly influence efflux pump expression (15, 16, 17). Recent reviews (7, 18) have emphasised the growing clinical importance of efflux-mediated resistance, emphasising the

urgent need for molecular surveillance of these mechanisms in hospital isolates.

In this context, the present study aimed to evaluate both the phenotypic presence and the molecular distribution of specific efflux pump-related genes, namely SdeXY-Y, SsmE, SdeCDE-D, SdeAB-B, and LUXR, in *S. marcescens* isolates obtained from patients with various infections in Diwaniyah, Iraq. These genes were thoughtfully selected based on their documented roles in multidrug resistance and their clinical significance in *S. marcescens*, supported by recent molecular and functional research (4, 19, 20).

## Materials and Methods

### Study Design

This study employed a cross-sectional, laboratory-based design and was carried out over the period from July 29 to November 26, 2024. Clinical samples were obtained from patients treated at Diwaniyah Teaching Hospital and the Women's and Children's Hospital, both located within Diwaniyah Governorate, Iraq.

### Sample Collection and Bacterial Isolation

In total, 200 clinical specimens were collected from individuals presenting with urinary tract infections (n=91), diarrhoea (n=62), and bloodstream infections (n=47). These samples were cultured on selective media, and colonies exhibiting morphological features consistent with *Serratia marcescens* were subjected to standard biochemical identification procedures. A total of twenty isolates were confirmed as *S. marcescens* and included in the study, with isolates selected consecutively until the target sample size was reached.

### Phenotypic Detection of Efflux Pump Activity

Phenotypic assessment of efflux pump activity was conducted using the ethidium bromide-agar cartwheel method as described by Martins *et al.* (2011). Bacterial suspensions were adjusted to a turbidity of 0.5 McFarland and streaked radially onto tryptic soy agar plates containing different concentrations of ethidium bromide (0.5, 1.0, 1.5, and 2.0  $\mu\text{g/mL}$ ). Following incubation at 37°C for 18–24 hours, plates were examined under UV light. A positive outcome, indicating active efflux, was identified when bacterial colonies showed weak or no fluorescence, signifying ethidium bromide extrusion. Conversely, intense

fluorescence was interpreted as a negative result for efflux pump function.

#### Genomic DNA Extraction

Genomic DNA was extracted from overnight cultures of *S. marcescens* using a commercial bacterial DNA extraction kit (ABM®, Canada), following the manufacturer's instructions. DNA purity and concentration were quantified using a NanoDrop™ spectrophotometer at 260/280 nm. Extracted DNA samples were stored at -20°C until further analysis.

#### Polymerase Chain Reaction (PCR) for Efflux Pump Gene Detection

Polymerase chain reaction (PCR) assays were performed to detect five genes associated with efflux pump activity: *SdeXY-Y*, *SsmE*, *SdeCDE-D*, *SdeAB-B*, and *LUXR*. The universal 16S rRNA

gene served as a marker for species confirmation. Primer sequences and PCR cycling parameters are detailed in Table 1. Each 25 µL reaction mixture included 2.5 µL of 10× PCR buffer, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 0.5 µM of each primer, 1 U of Taq DNA polymerase (Thermo Scientific®), and 2 µL of template DNA. Amplification was carried out using a thermal cycler (Bio-Rad®). All PCR runs incorporated positive controls, comprising previously characterised *S. marcescens* strains harbouring the target genes, and negative controls lacking DNA. Amplified products were separated on 1.5% agarose gels stained with ethidium bromide, then visualised under UV transillumination.

**Table 1. Primer sequences and PCR cycling conditions for target genes**

Gene	Primer Sequence (5'-3')	Product Size (bp)	Annealing Temp (°C)	Cycles
<i>SdeXY-Y</i>	F: CAGTGGTCGCTTCAACATTC R: GCTTACCTGGTGCTTCTTCC	488	58	35
<i>SsmE</i>	F: ATGACCGCGTTGTCATCATT R: TTAGGCGTTTCGAGGATGTTG	188	55	35
<i>SdeCDE-D</i>	F: CGTTGACGACATTGACGAGT R: ACGAGGATGGTTTCGTCCT	417	56	35
<i>SdeAB-B</i>	F: AGCAGCGTATCGACCTTGTA R: CTGGTTGATCTGCGTCTTTC	415	57	35
<i>LUXR</i>	F: AAGCGCTTGCTGTGTTTGTA R: CTGCTGATCGAGGAAGTTCA	208	54	35
16S rRNA	F: AGAGTTTGATCCTGGCTCAG R: TACGGTTACCTTGTTACGACTT	1500	55	35

#### Data Analysis

Data regarding the prevalence of efflux pump genes were expressed as percentages. Descriptive statistical methods summarise both phenotypic and genotypic data. Due to the limited sample size, inferential statistical testing was not performed; nonetheless, qualitative descriptions of observed trends were included.

Out of the 20 *Serratia marcescens* clinical isolates tested, 8 (40%) demonstrated positive efflux activity using the ethidium bromide-agar cartwheel method (EtBr-CW). Fluorescence intensity under ultraviolet light was used to differentiate efflux-positive (weak or no fluorescence) from efflux-negative (strong fluorescence) isolates. The distribution of fluorescence at different EtBr concentrations is summarised in Table 2.

#### Results

##### Phenotypic Detection of Efflux Pump Activity


**Table 2: Fluorescence pattern of *S. marcescens* isolates on EtBr-containing agar plates (interpreted for efflux pump activity)**

Isolate ID	0.5 µg/mL	1.0 µg/mL	1.5 µg/mL	2.0 µg/mL	Efflux Pump Activity
Sm1	–	–	–	+	Negative
Sm2	+	+	–	–	Positive
Sm3	–	–	–	–	Negative
Sm4	–	–	–	–	Negative
Sm5	–	–	–	–	Negative
Sm6	–	+	+	–	Positive
Sm7	+	–	–	–	Positive
Sm8	+	+	–	–	Positive

Sm9	–	–	–	–	Negative
Sm10	+	–	–	+	Positive
Sm11	+	+	+	+	Positive
Sm12	+	+	–	–	Positive
Sm13–Sm20	–	–	–	–	Negative

(+ = Fluorescent; – = No fluorescence; ND = Not detected)

Representative examples of fluorescence differential staining at various EtBr isolates are shown in Figure 1, demonstrating concentrations.



**Figure 1: Fluorescent responses of *S. marcescens* isolates stained with ethidium bromide (0.5–2.0 µg/mL) under UV light. Positive efflux activity was indicated by reduced fluorescence intensity**

*Molecular Detection of Efflux Pump and Quorum Sensing Genes*  
PCR analysis confirmed the presence of five target genes associated with efflux activity and


quorum sensing. The distribution of these genes among the 20 *S. marcescens* isolates is summarised in Table 3.

**Table 3: Frequency of efflux and quorum-sensing genes detected by PCR**


Gene	No. of Positive Isolates	Prevalence (%)
LUXR	20	100%
SdeCDE-D	19	95%
SdeAB-B	18	90%
SdeXY-Y	12	60%
SsmE	9	45%

Amplification of gene products was confirmed by agarose gel electrophoresis. Representative gel


images for each gene are shown in Figures 2 to 6.




**Figure 2: PCR amplification of SdeXY-Y gene (488 bp) in *S. marcescens* isolates**




**Figure 3: PCR amplification of SsmE gene (188 bp)**



**Figure 4. PCR amplification of SdeCDE-D gene (417 bp)**



**Figure 5. PCR amplification of SdeAB-B gene (415 bp)**



**Figure 6. PCR amplification of the LUXR gene (208 bp)**

Each PCR reaction included appropriate positive and negative controls. Gene-specific bands were observed at expected product sizes, confirming

successful amplification. Isolate-wise presence/absence for each gene is detailed in Table 4.

**Table 4: Presence (+) or Absence (–) of Efflux Pump and Quorum Sensing Genes in *Serratia marcescens* Isolates**

Isolate ID	SdeXY-Y	SsmE	SdeCDE-D	SdeAB-B	LUXR
Sm1	–	–	+	+	+
Sm2	+	–	+	+	+
Sm3	–	–	+	+	+
Sm4	–	+	+	+	+
Sm5	+	–	+	+	+
Sm6	+	+	+	+	+
Sm7	–	–	+	–	+
Sm8	+	+	+	+	+
Sm9	+	–	+	+	+
Sm10	–	+	+	+	+
Sm11	+	+	+	+	+
Sm12	+	–	+	+	+
Sm13	–	–	–	–	+
Sm14	+	–	+	+	+
Sm15	–	–	+	+	+
Sm16	+	+	+	+	+
Sm17	–	–	+	+	+
Sm18	–	+	+	+	+
Sm19	+	+	+	+	+
Sm20	+	–	+	+	+

+ = Gene detected by PCR; – = Gene not detected; Sm1–Sm20 = *S. marcescens* isolates 1 through 20

## Discussion

This investigation focused on the detection and distribution of key efflux pump and quorum sensing genes within *Serratia marcescens* isolates derived from clinical specimens in Diwaniyah, Iraq. Employing both phenotypic and molecular methodologies, we observed that approximately 40% of the isolates demonstrated phenotypic efflux activity, while a majority harboured multiple genes associated with efflux mechanisms. These findings emphasise the important role of efflux systems in shaping the antimicrobial resistance profile of *S. marcescens*, corroborating previous research (7, 8, 10).

A particularly noteworthy aspect of our study is the observed discrepancy between phenotypic results and genotypic data. Despite the widespread presence of efflux pump genes such as SdeXY-Y, SsmE, SdeCDE-D, and SdeAB-B, only 40% of the isolates exhibited phenotypic efflux activity when tested with the ethidium bromide cartwheel method. This inconsistency may be attributable to various factors, including differences in gene expression, mutations rendering genes non-functional, regulatory controls, or gene silencing during in vitro experimentation (12, 21). Efflux activity is often modulated by environmental stimuli, stress responses, and quorum sensing signals,

conditions that might not have been fully replicated in the experimental setup.

Interestingly, the LUXR gene was detected in all 20 isolates (100%), which aligns with the well-established conserved function of LUXR homologues in quorum sensing among many Gram-negative bacteria, including *S. marcescens* (15, 17). These regulator genes can influence biofilm development, pathogenicity, and even efflux pump expression, hinting at a possible connection between quorum sensing and antimicrobial resistance mechanisms (16). Their universal presence emphasises the importance of LUXR in maintaining bacterial adaptability, particularly in clinical environments. The RND-type efflux pump genes SdeCDE-D and SdeAB-B were found in 95% and 90% of isolates, respectively. These genes encode multidrug efflux systems capable of removing a broad scope of antibiotics, including  $\beta$ -lactams, fluoroquinolones, tetracyclines, and chloramphenicol (13, 22, 23, 24). Their high prevalence confirms previous observations from Iraq and other regions (4, 14), emphasising the clinical significance of efflux-based resistance.

The SdeXY-Y gene was identified in 60% of the isolates. This efflux system has been associated with resistance to tigecycline, erythromycin, novobiocin, and ciprofloxacin (11, 12, 13).

Variations in the presence of the SdeXY-Y gene among isolates may reflect selective pressures stemming from antimicrobial usage or local clonal dissemination. Notably, 45% of isolates carried the SsmE gene, which encodes an SMR-type efflux pump involved in resistance to norfloxacin and ethidium bromide (25). Although less common, the role of SsmE may become more prominent under particular environmental or antimicrobial conditions.

From a clinical standpoint, the presence of multiple efflux pump genes indicates that infections caused by *S. marcescens* in this environment may pose challenges to treatment with standard antibiotics. These efflux mechanisms are known to limit the intracellular concentration of drugs such as fluoroquinolones, tetracyclines, aminoglycosides, and chloramphenicol, potentially leading to treatment failures (7, 9). Besides, the simultaneous presence of quorum-sensing regulators like LUXR alongside efflux genes raises concerns about enhanced biofilm formation and the organism's ability to persist in cases of catheter-associated or chronic infections.

The detection of efflux-related genes across isolates from diverse infection sites, including urine, blood, and stool, emphasises the organism's remarkable adaptability and the necessity for strong antimicrobial stewardship and infection control measures. Clinical microbiology laboratories should consider incorporating fast molecular diagnostics for efflux genes into routine resistance profiling, especially in tertiary hospitals where *S. marcescens* is increasingly recognised as an important pathogen.

#### Study limitations

This investigation is subject to several limitations. Primarily, the relatively small sample size ( $n = 20$ ) constrains the broader applicability of the findings and restricts the use of inferential statistical analyses. Besides, the study was geographically confined to a single location, Diwaniyah, Iraq, and thus may not represent the prevalence or genetic diversity of efflux mechanisms in other regions. The absence of antimicrobial susceptibility testing, including minimum inhibitory concentration (MIC) determinations, limits the ability to directly associate the presence of efflux genes with phenotypic resistance. Lastly, the study did not evaluate gene expression levels or the effects of efflux pump inhibitors, which would have offered deeper insight into their functional significance. Going forward, larger, multicentre studies that integrate phenotypic resistance data with transcriptomic or proteomic analyses are essential. What's more, exploring the therapeutic

potential of efflux pump inhibitors could open new avenues for combating resistant infections.

#### Conclusion

This investigation offers compelling evidence that clinical isolates of *\*Serratia marcescens\** obtained from Diwaniyah, Iraq, carry various efflux pump genes, notably LUXR, SdeCDE-D, and SdeAB-B, which were detected most frequently. While phenotypic efflux activity was observed in only 40% of the isolates, the widespread presence of these efflux-related genes indicates a considerable potential for antimicrobial resistance, especially against  $\beta$ -lactams, fluoroquinolones, and tetracyclines. The consistent detection of the LUXR gene emphasises the probable involvement of quorum sensing in regulating efflux mechanisms and other virulence factors.

Despite these major insights, the study's scope was constrained by a limited sample size, the absence of comprehensive antibiotic susceptibility profiles, and its single-centre setting. These limitations emphasise the necessity for larger-scale, multi-institutional research that integrates molecular analyses, phenotypic assessments, and clinical outcome data. Future investigations should focus on evaluating the expression levels of these efflux genes under various antibiotic pressures and exploring the potential of efflux pump inhibitors as adjunct treatments.

From a public health and clinical standpoint, genes such as SdeCDE-D and regulatory elements like LUXR represent promising targets for resistance mitigation strategies. Strengthening surveillance efforts and incorporating molecular diagnostics into routine microbiology protocols could greatly enhance antimicrobial stewardship and infection control measures within hospital environments.

#### List of Abbreviations

Bp: Base pair  
 DNA: Deoxyribonucleic Acid  
 EtBr: Ethidium Bromide  
 EtBr-CW: Ethidium Bromide–Agar Cartwheel Method  
 IRB: Institutional Review Board  
 LUXR: LuxR-type quorum-sensing regulator gene  
 MIC: Minimum Inhibitory Concentration  
 MDR: Multidrug Resistance  
 PCR: Polymerase Chain Reaction  
 QS: Quorum Sensing  
 RND: Resistance-Nodulation-Division (efflux pump family)  
 RNA: Ribonucleic Acid  
 SMR: Small Multidrug Resistance (efflux pump family)



UTI: Urinary Tract Infection  
UV: Ultraviolet

## Declarations

### Ethics approval and consent to participate

This study was conducted following the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board (IRB) of the University of Al-Qadisiyah, Iraq (Approval Reference No.: [EDU-37-11/12/2024]). Before sample collection, written informed consent was obtained from all participants or, in the case of minors, from their parents or legal guardians. Confidentiality and anonymity of patient data were strictly maintained throughout the study.

### Consent for Publication

All the authors gave consent for the publication of the work under the Creative Commons Attribution Non-Commercial 4.0 license.

### Availability of Data

Data for this work is available from the authors and may be provided upon reasonable request.

### Conflicts of Interest

None.

### Funding

None.

### Authors' contributions

KMM: Contributed to the procurement of samples, carried out part of the experimental work and statistical analysis, and was involved in writing and revising the manuscript.

HAN: Conceived of the research, led the design and implementation of the study, was involved in the data interpretation, and took responsibility for manuscript editing, review and final approval.

### Acknowledgments

The authors of this work sincerely thank the University of Al-Qadisiyah, especially, the Department of Biology/ Education College, for the support and assistance.

## References

1. Nelson GE, Greene MH. Enterobacteriaceae. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 9th ed. Elsevier; 2020.
2. Radeva S, Milena B, Denis N. History and presence of *Serratia marcescens*. *Acta Microbiol Bulg*. 2023;39(3). <https://doi.org/10.59393/amb23390303>
3. Salim WM, Luma HA. Molecular detection of *Serratia marcescens* isolated from different

clinical cases in Wasit province, Iraq. *J Adv Res Med Health Sci*. 2023;9(11):51-56. <https://doi.org/10.53555/cjp73776>

4. Hamzah AS, Ali JS. Evaluation of mutations in efflux pump genes in *Serratia marcescens*. *J Nat Sci Biol Med*. 2023;14:39–44.
5. Blanco P, Hernando-Amado S, Reales-Calderon JA, Corona F, Lira F, Alcalde-Rico M, Bernardini A, Sanchez MB, Martinez JL. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. *Microorganisms*. 2016 Feb 16;4(1):14. <https://doi.org/10.1016/j.biochi.2016.04.012>
6. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. *Biochimie*. 2005;87:1137–1147. <https://doi.org/10.1016/j.biochi.2005.04.012>
7. Gaurav A, Perwez B, Mahak S, Shivam P, Ranjana P. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. *Microbiology*. 2023;169:001333. <https://doi.org/10.1099/mic.0.001333>
8. Hernando-Amado S, Blanco P, Alcalde-Rico M, Corona F, Reales-Calderón JA, Sánchez MB, Martínez JL. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. *Drug Resistance Updates*. 2016 Sep 1;28:13-27. <https://doi.org/10.1016/j.drug.2016.06.007>
9. Blair JM, Bavro VN, Ricci V, Modi N, Cacciottolo P, Kleinekathöfer U, Ruggerone P, Vargiu AV, Baylay AJ, Smith HE, Brandon Y. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. *Proceedings of the National Academy of Sciences*. 2015 Mar 17;112(11):3511-6. <https://doi.org/10.1073/pnas.1419939112>
10. Liang Z, Jiahao S, Jing L, et al. Prevalence and characterization of *Serratia marcescens* isolated from clinical bovine mastitis cases in Ningxia Hui Autonomous Region of China. *Infect Drug Resist*. 2023;16:2727–2735. <https://doi.org/10.2147/IDR.S408632>
11. Chen J, Kuroda T, Huda MN, Mizushima T, Tsuchiya T. An RND-type multidrug efflux pump SdeXY from *Serratia marcescens*. *Journal of Antimicrobial Chemotherapy*. 2003 Aug 1;52(2):176-9. <https://doi.org/10.1093/jac/dkg308>
12. Hornsey M, Ellington MJ, Doumith M, Hudson S, Livermore DM, Woodford N. Tigecycline resistance in *Serratia marcescens* associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and ceftiofime. *Journal of Antimicrobial Chemotherapy*. 2010 Mar 1;65(3):479-82. <https://doi.org/10.1093/jac/dkp475>



13. Toba S, Minato Y, Kondo Y, Hoshikawa K, Minagawa S, Komaki S, Kumagai T, Matoba Y, Morita D, Ogawa W, Gotoh N. Comprehensive analysis of resistance-nodulation-cell division superfamily (RND) efflux pumps from *Serratia marcescens*, Db10. Scientific reports. 2019 Mar 19;9(1):4854. <https://doi.org/10.1038/s41598-019-41237-7>
14. Ferreira RL, Rezende GS, Damas MSF. Characterization of KPC-producing *Serratia marcescens* in an intensive care unit of a Brazilian tertiary hospital. *Front Microbiol.* 2020;11:956. <https://doi.org/10.3389/fmicb.2020.00956>
15. Miller C, Gilmore J. Detection of quorum-sensing molecules for pathogenic molecules using cell-based and cell-free biosensors. *Antibiotics.* 2020;9:259. <https://doi.org/10.3390/antibiotics9050259>
16. Sabatini S, Piccioni M, Felicetti T, De Marco S, Manfroni G, Pagiotti R, Nocchetti M, Cecchetti V, Pietrella D. Investigation on the effect of known potent *S. aureus* NorA efflux pump inhibitors on the staphylococcal biofilm formation. RSC Advances. 2017;7(59):37007-14. <https://doi.org/10.1039/C7RA03859C>
17. Van Houdt R, Moons P, Aertsen A, Jansen A, Vanoirbeek K, Daykin M, Williams P, Michiels CW. Characterization of a luxI/luxR-type quorum sensing system and N-acyl-homoserine lactone-dependent regulation of exo-enzyme and antibacterial component production in *Serratia plymuthica* RVH1. *Research in Microbiology.* 2007 Mar 1;158(2):150-8. <https://doi.org/10.1016/j.resmic.2006.11.008>
18. Tavares-Carreón F, De Anda-Mora K, Rojas-Barrera IC, Andrade A. *Serratia marcescens* antibiotic resistance mechanisms of an opportunistic pathogen: a literature review. *PeerJ.* 2023;11:e14399. <https://doi.org/10.7717/peerj.14399>
19. Sandner-Miranda L, Vinuesa P, Cravioto A, Morales-Espinosa R. The genomic basis of intrinsic and acquired antibiotic resistance in the genus *Serratia*. *Front Microbiol.* 2018;9:828. <https://doi.org/10.3389/fmicb.2018.00828>
20. Dalvi SD, Worobec EA. Gene expression analysis of the SdeAB multidrug efflux pump in antibiotic-resistant clinical isolates of *Serratia marcescens*. *Indian J Med Microbiol.* 2012;30(3):302–307. <https://doi.org/10.4103/0255-0857.99491>
21. Martins M, Viveiros M, Couto I, Costa SS, Pacheco T, Fanning S, Pages JM, Amaral L. Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. *In vivo.* 2011 Mar 1;25(2):171-8.
22. Begic S, Worobec EA. Characterization of the *Serratia marcescens* SdeCDE multidrug efflux pump studied via gene knockout mutagenesis. *Can J Microbiol.* 2008;54(5):411–416. doi:10.1139/w08-019. <https://doi.org/10.1139/W08-019>
23. Begic S, Worobec EA. The role of the *Serratia marcescens* SdeAB multidrug efflux pump and TolC homologue in fluoroquinolone resistance studied via gene-knockout mutagenesis. *Microbiology.* 2008;154(2):454–461. <https://doi.org/10.1099/mic.0.2007/012427-0>
24. Tavares-Carreón F, Karla D, Idalia CR, Angel A. *Serratia marcescens* antibiotic resistance mechanisms of an opportunistic pathogen: a literature review. *PeerJ.* 2022;11:e14399. <https://doi.org/10.7717/peerj.14399>
25. Minato Y, Shahcheraghi F, Ogawa W, Kuroda T, Tsuchiya T. Functional gene cloning and characterization of the SsmE multidrug efflux pump from *Serratia marcescens*. *Biol Pharm Bull.* 2008;31:516–519. <https://doi.org/10.1248/bpb.31.516>